CRISPR-cas technology and use in antiviral development

Throughout history, viral diseases have periodically reached pandemic proportions and have had devastating effects on human history. With the advancement of science and technology, antivirals have been developed and continue to be developed in the fight against viral diseases. The difficulty in the development of antirival has tried to use new technologies in the development of antiviral. One of these new technologies is the CRISPR/Cas system. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) defines a series of DNA sequences called clusters of regularly interspaced palindromic repeats, and CAS defines endonucleases that use CRISPR sequences as a guide to recognize and cut specific DNA chains related to the CRISPR region. While protein engineering systems defined before CRISPR/Cas systems can be off-target and cause undesirable results, the CRISPR/Cas system reduces this risk by Watson-Crick base pairing. In the fight against viral infections of humans and animals, vaccine protection methods are widely used due to the problems in developing antivirals. On the other hand, the difficulty of vaccination, inadequacies in long-term immunity and the emergence of new infections or epidemics due to mutational changes in viruses pave the way for developing new antivirals. This article emphasizes the history and working areas of CRISPR-Cas technology and the potential applications of this method in antiviral development for human and animal viruses